Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials

In RCTs (n=891 & 877), this oral antagonist of prostaglandin D 2 receptor did not reduce sputum eosinophils and improve lung function or lead to statistically significant reduction in asthma exacerbations; modest reductions in exacerbation rates were observed with 450mg dose.

The Lancet Respiratory Medicine